Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned an average recommendation of “Hold” from the five analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $13.75.

Several brokerages recently issued reports on TBPH. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th.

Theravance Biopharma Stock Down 0.3 %

NASDAQ:TBPH opened at $9.49 on Thursday. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $11.71. The stock has a market cap of $464.27 million, a P/E ratio of -9.43 and a beta of 0.25. The business’s 50-day moving average price is $8.42 and its two-hundred day moving average price is $8.70.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, equities research analysts expect that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 322,743 shares in the company, valued at approximately $2,904,687. This trade represents a 1.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in Theravance Biopharma during the 2nd quarter valued at approximately $986,000. Bank of Montreal Can lifted its stake in shares of Theravance Biopharma by 141.0% in the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after purchasing an additional 93,702 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Theravance Biopharma by 16.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock valued at $474,000 after purchasing an additional 7,509 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Theravance Biopharma by 38.4% in the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after purchasing an additional 91,679 shares during the period. Finally, Marshall Wace LLP raised its holdings in Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after purchasing an additional 135,426 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.